Gotham Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Gotham Asset Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,989	Closed	-$56K	–	1353
2022 Q4	$56K	Buy	+2,989	New	+$67.7K	﹤0.01%	1195
2020 Q3	–	Sell	-6,811	Closed	-$2.2M	–	1085
2020 Q2	$2.2M	Buy	6,811 +1,950	+40%	+$313K	0.07%	364
2020 Q1	$434K	Buy	+4,861	New	+$300K	0.01%	744
2016 Q1	–	Sell	-3,094	Closed	-$249K	–	1028
2015 Q4	$249K	Buy	+3,094	New	+$246K	﹤0.01%	784

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gotham Asset Management's INO Position: Q1 2023 in Review

Gotham Asset Management sold out of Inovio Pharmaceuticals (INO) in Q1 2023, closing a stake of 2,989 shares — an estimated $56K sold.

Gotham Asset Management first reported a position in INO in Q4 2015 and held it in 4 quarters. The position peaked at $2.2M in Q2 2020. 174 funds tracked by Wall St. Rank hold INO as of Q1 2023.

Gotham Asset Management reported no remaining Inovio Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Gotham Asset Management sold 2,989 Inovio Pharmaceuticals shares in Q1 2023, an estimated $56K.
Gotham Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2015 and held it in 4 quarters.
Gotham Asset Management's Inovio Pharmaceuticals position peaked at $2.2M in Q2 2020.
174 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2023.

Based on Gotham Asset Management's 13F filing for Q1 2023, filed 15 May 2023.